MX2012011721A - Derivados benzamida novedosos. - Google Patents

Derivados benzamida novedosos.

Info

Publication number
MX2012011721A
MX2012011721A MX2012011721A MX2012011721A MX2012011721A MX 2012011721 A MX2012011721 A MX 2012011721A MX 2012011721 A MX2012011721 A MX 2012011721A MX 2012011721 A MX2012011721 A MX 2012011721A MX 2012011721 A MX2012011721 A MX 2012011721A
Authority
MX
Mexico
Prior art keywords
benzamide derivatives
receptors
same
novel benzamide
present
Prior art date
Application number
MX2012011721A
Other languages
English (en)
Inventor
Weon-Bin Im
Sung-Hak Choi
Sun-Ho Choi
Hyun-Jung Sung
Soon-Hoe Kim
Ju-Hee Sohn
Mi-Yeon Kim
Kang-Hun Cho
Tae-Kyoung Sohn
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of MX2012011721A publication Critical patent/MX2012011721A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Abstract

La presente invención proporciona un derivado de benzamida novedoso o una sal farmacéuticamente aceptable de la misma, un método para preparar la misma, y un agonista del receptor 5-HT4 que contiene la misma como un ingrediente activo. Los derivados de benzamida de la presente invención tienen una afinidad superior para los receptores 5-HT4, una capacidad para reducir un tiempo de vaciado gástrico y una baja toxicidad, y consecuentemente son efectivos terapéuticamente para el tratamiento de una variedad de enfermedades asociadas con los receptores 5-HT4.
MX2012011721A 2010-04-23 2011-04-18 Derivados benzamida novedosos. MX2012011721A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100038039A KR101180174B1 (ko) 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체
PCT/KR2011/002759 WO2011132901A2 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives

Publications (1)

Publication Number Publication Date
MX2012011721A true MX2012011721A (es) 2012-12-17

Family

ID=44834616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011721A MX2012011721A (es) 2010-04-23 2011-04-18 Derivados benzamida novedosos.

Country Status (19)

Country Link
US (1) US9221790B2 (es)
EP (1) EP2560955B1 (es)
JP (1) JP5564147B2 (es)
KR (1) KR101180174B1 (es)
CN (1) CN102844301B (es)
AU (1) AU2011243393B2 (es)
BR (1) BR112012026509B1 (es)
CA (1) CA2794176C (es)
ES (1) ES2594708T3 (es)
HK (1) HK1176061A1 (es)
IL (1) IL222491A (es)
MX (1) MX2012011721A (es)
MY (1) MY162554A (es)
NZ (1) NZ602612A (es)
RU (1) RU2536688C2 (es)
SG (1) SG184350A1 (es)
UA (1) UA107702C2 (es)
WO (1) WO2011132901A2 (es)
ZA (1) ZA201207903B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101457789B1 (ko) 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법
ES2897946T3 (es) * 2013-07-25 2022-03-03 Dong A St Co Ltd Método para preparar un derivado de benzamida, intermedio novedoso utilizado en la preparación de la benzamida y método para preparar un intermedio novedoso
CN104230889A (zh) * 2014-08-29 2014-12-24 南京大学 环丙沙星衍生物及其制备方法与用途
KR102394635B1 (ko) * 2015-03-31 2022-05-09 (주)아모레퍼시픽 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
KR970702247A (ko) 1994-03-30 1997-05-13 고야 마사시 벤조산 화합물 및 이들의 약제로서의 용도(benzoic acid compound and use thereof as medicine)
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
BR9915735A (pt) 1998-11-20 2001-09-04 Hoffmann La Roche Antagonistas receptores de ccr-3 de piperidina
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
AU2008241692B2 (en) 2007-04-19 2011-02-10 Dong-A Pharm. Co., Ltd. DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010062959A1 (en) 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
BR112012023139A2 (pt) 2010-03-24 2018-06-26 Dong A Pharm Co Ltd composição farmacêutica para a prevenção ou o tratamento de doença do fígado gordo não alcóolico e o método para a prevenção ou tratamento de doença do fígado gordo não alcóolico usando a mesma.
US20140155609A9 (en) 2010-11-24 2014-06-05 Dong-A St Co., Ltd. Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
WO2012070700A1 (ko) 2010-11-24 2012-05-31 동아제약주식회사 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물

Also Published As

Publication number Publication date
JP2013525344A (ja) 2013-06-20
AU2011243393A1 (en) 2012-10-18
IL222491A (en) 2016-07-31
CA2794176C (en) 2015-12-15
US9221790B2 (en) 2015-12-29
EP2560955A2 (en) 2013-02-27
HK1176061A1 (en) 2013-07-19
KR20110118446A (ko) 2011-10-31
MY162554A (en) 2017-06-15
RU2012150037A (ru) 2014-05-27
ZA201207903B (en) 2013-06-26
UA107702C2 (en) 2015-02-10
CN102844301A (zh) 2012-12-26
BR112012026509B1 (pt) 2021-01-19
WO2011132901A3 (en) 2012-01-26
BR112012026509A2 (pt) 2017-10-31
RU2536688C2 (ru) 2014-12-27
EP2560955A4 (en) 2013-09-11
AU2011243393B2 (en) 2014-07-17
WO2011132901A2 (en) 2011-10-27
US20130085160A1 (en) 2013-04-04
JP5564147B2 (ja) 2014-07-30
EP2560955B1 (en) 2016-06-29
CN102844301B (zh) 2015-04-22
SG184350A1 (en) 2012-11-29
IL222491A0 (en) 2012-12-31
ES2594708T3 (es) 2016-12-22
NZ602612A (en) 2014-11-28
KR101180174B1 (ko) 2012-09-05
CA2794176A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
NZ747259A (en) Soluble c5ar antagonists
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
ZA200706354B (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
MX369576B (es) Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4.
MY162554A (en) Novel benzamide derivatives
MX2009009445A (es) Derivados novedosos de benzamida y proceso para la preparacion de los mismos.
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
IN2012DN02556A (es)
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
TN2013000257A1 (en) Immunosuppressant formulations
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
TW200716607A (en) Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
JO3610B1 (ar) مشتقات كربوكساميد
EA201692298A1 (ru) Производные карбоксамидов
MX2013006768A (es) Moduladores de receptor de glucagon.
WO2009076408A3 (en) 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
AU2018279669A8 (en) Carboxylic acid derivative as at AT2R receptor antagonist
MX2009012761A (es) Neramexano para el tratamiento de nistagmo.
WO2012134231A3 (ko) 카나비노이드 수용체（ｃｂ１） 길항제로서의 벤즈아미드 유도체
WO2012072791A3 (en) 2-(1-phenyl-4,5,6,7-tetrahydro-1h-indazol-4-yl)ethylamine derivatives useful as sigma receptor inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal